Investors in PEPG Can Take the Lead in PepGen Securities Fraud Lawsuit With …

Investors who suffered financial losses exceeding $50,000 due to PepGen’s actions between March 7, 2024, and March 3, 2025, are being encouraged to contact Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson to explore potential options. Faruqi & Faruqi, LLP, a renowned national securities law firm, is currently investigating potential claims against PepGen Inc. (“PepGen” or the “Company”) and reminds investors that the deadline to seek the role of lead plaintiff in a federal securities class action against the Company is August 11, 2025.

The complaint alleges that PepGen and its executives violated federal securities laws by disseminating false and misleading statements or failing to disclose crucial information. Specifically, it’s claimed that PGN-EDO51 was not as effective or safe as represented, the CONNECT2 study had significant risks for FDA approval, and PepGen was likely to halt the CONNECT2 study due to critical issues. Consequently, the company’s public statements were alleged to be misleading and false during the relevant period.

Following a press release on July 30, 2024, detailing positive clinical data from the CONNECT1 study, PepGen’s stock price plummeted by $5.55 per share, or 32.69%, the next day. Subsequent updates from the company led to further declines in its stock value. On December 16, 2024, PepGen’s stock fell by $0.17 per share, or 3.63%, following an announcement of a clinical hold notice from the FDA regarding the CONNECT2 study. Similarly, on January 29, 2025, PepGen disclosed safety concerns in the CONNECT1 study, leading to a $0.40 per share, or 21.74%, decrease in stock price on January 30, 2025.

PepGen announced on March 4, 2025, its decision to temporarily pause the CONNECT2 study, resulting in a stock price drop of $0.53 per share, or 18.86%. Finally, on May 28, 2025, the company disclosed that PGN-EDO51 did not meet target dystrophin levels, leading to the discontinuation of its DMD programs.

The lead plaintiff in this case is the investor with the most significant financial stake seeking relief for the class and is responsible for overseeing the litigation. Members of the class can choose to become lead plaintiffs through their counsel or stay as absent class members. Faruqi & Faruqi, LLP encourages anyone with relevant information on PepGen’s actions to contact the firm, including whistleblowers, shareholders, former employees, and others.

For more information on the PepGen class action, individuals are advised to visit the firm’s website or contact Faruqi & Faruqi partner Josh Wilson directly. Faruqi & Faruqi, LLP makes it clear that prior results do not guarantee future outcomes, and all communications will be confidential.